HCPLive
2014 CMSC/ACTRIMS Cooperative Annual Meeting

2014 CMSC/ACTRIMS Cooperative Annual Meeting | CMSC 2014

The goal of the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Sixth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is to provide multiple sclerosis health care professionals with the most up-to-date information to positively impact both clinical practice and research.

Conference Coverages

What is the Most Effective Treatment Strategy for Patients with Secondary Progressive Multiple Sclerosis?
What is the Most Effective Treatment Strategy for Patients with Secondary Progressive Multiple Sclerosis?
Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.
Alemtuzumab: Do the Benefits Outweigh the Risks in Treating Multiple Sclerosis?
Session at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers debates whether the side effects associated with alemtuzumab, a novel anti-CD52 monoclonal antibody, might ultimately prevent its approval for the treatment of multiple sclerosis, despite evidence of clinical effectiveness.
Peginterferon Beta-1a Associated with Low Incidence of Treatment-emergent Antibodies in Relapsing-Remitting Multiple Sclerosis
Low rates of immunogenicity observed in study support the potential benefits of subcutaneous peginterferon beta-1a in the treatment of patients with relapsing-remitting multiple sclerosis.
Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta-1a
The reductions in brain volume often seen in patients with chronic relapsing–remitting multiple sclerosis may be reduced by treatment with interferon beta-1a, though treatment may be affected by the patient’s immunologic status.
Disability Progression in Patients Who Switch from Natalizumab to Fingolimod or Injectable Therapies
Analysis of NARCOMS data showed that switching from natalizumab to fingolimod or injectable therapy was associated with an increased likelihood of reported disability progression.
New Focus and Strategies for Managing Primary Progressive Multiple Sclerosis
Primary MS is characterized by neurodegeneration with neuroaxonal injury and diffuse inflammation; disease progression is linked with age. Effective management calls for symptom-specific medical management combined with wellness and health maintenance measures.
New Trials Testing Agents for Treating Relapsing-Remitting Multiple Sclerosis
Although there are more treatment options than ever before available to patients and clinicians, new approaches are needed to treat acute exacerbations, as well as new options that can help meet the long-term goals of symptomatic management and rehabilitation.

Most Popular

$vacMongoViewPlus$ $vAR$